← Atlas Theme · spans 1 topics
Oral weight-loss formulations cannot replicate the commercial momentum of their injectable predecessors.
Underperforming sales and severe gastrointestinal side effects are stalling the market adoption of early oral obesity medications compared to high-growth injectable franchises.
1
Topics it spans
3
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
GLP-1 Cross-Sector Effects
Eli Lilly Commands Q2 2026 with Blockbuster Earnings: Tirzepatide Surges as Oral Foundayo Misses Slightly Despite massive expectations for non-peptide small molecules, Eli Lilly's daily oral pill Foundayo missed early commercial forecasts.
GLP-1 Cross-Sector Effects
Kailera's Oral GLP-1 Pill HRS-7535 Succeeds in Phase 3 China Trial but Sparks Severe Tolerability Concerns Extremely high rates of nausea and vomiting threaten to limit the commercial viability and adoption of next-generation oral formulations.
GLP-1 Cross-Sector Effects
Novo Nordisk Navigates Q2 2026 Setbacks: Wegovy Pill Sales Miss and CagriSema Clinical Failure Novo Nordisk's oral Wegovy tablet underperformed expectations, highlighting the commercial friction facing early oral metabolic drugs.